Pfizer Oncology Focusing On Genetic Drivers Of Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s latest refinement to its oncology R&D strategy includes an increased focus on personalized medicine, concentrating on biomarkers for patient selection and development of companion diagnostics.